Skip to main content
Top
Published in: Journal of Nephrology 5/2023

16-02-2023 | Vaccination | Lessons for the Clinical Nephrologist

Steroid resistant nephrotic syndrome with collapsing focal segmental glomerulosclerosis in a 12-year-old Japanese female after SARS-CoV-2 vaccination

Authors: Tomoko Horinouchi, Chika Ueda, Hideaki Kitakado, Norishige Yoshikawa, Kandai Nozu

Published in: Journal of Nephrology | Issue 5/2023

Login to get access

Excerpt

A 12-year-old female was referred to our hospital because of severe edema. She had no specific past or family history, including prior infection. School-based urine screening had never detected any abnormalities. Two days after initial administration of the BNT162b2 (Pfizer/BioNTech) vaccine, edema began to gradually appear, and 8 days after the injection, her body weight had increased by 7 kg. Physical examination showed no purpura or arthralgia. Blood test showed severe hypoalbuminemia but no kidney dysfunction or hypocomplementemia (Table 1). Spot urinalysis showed nephrotic range proteinuria (urine protein to creatinine ratio: 12.8 g/gCr) and microhematuria, indicating nephrotic syndrome (NS). The screening polymerase chain reaction test for severe acute respiratory syndrome coronavirus (SARS-CoV-2) was negative. After admission, an albumin infusion was given as supportive treatment. Twenty-one days after vaccination and before initiating steroid treatment, kidney biopsy was performed. Light microscopy study (periodic acid-Schiff stain) revealed mesangial consolidation and loss of endocapillary patency and extracapillary epithelial proliferation, which is consistent with focal segmental glomerulosclerosis (FSGS) collapsing variant (Fig. 1A–C) [1]. Electron microscopy showed foot process fusion, but no tubuloreticular inclusions (Fig. 1D). Treatment with prednisolone 60 mg/m2/day with an upper limit of 60/mg/day was started according to clinical guidelines on childhood NS. Twenty-eight days after initiation of prednisolone, the patient had not achieved complete remission, so we started cyclosporine treatment and lisinopril therapy. Two cycles of methylprednisolone pulse therapy (1000 mg for 3 days) were also administered. Complete remission was finally achieved after 10 weeks of treatment (Table 1) with no adverse events. Comprehensive genetic testing with targeted sequence panel by next generation sequencing revealed no gene variants causing steroid-resistant NS or asymptomatic proteinuria (sTable 1) [2]. Human immunodeficiency virus (HIV) testing was not performed because of the low probability of infection. After complete remission, prednisolone was tapered, and therapy with cyclosporine and lisinopril was continued. At the last observation (6 months later), eGFR tended to be lower compared with values at the beginning of the disease. It is impossible to determine whether this is the effect of cyclosporine or the progression of the underlying disease. Follow-up renal biopsy is scheduled for 2 years after the start of treatment.
Table 1
Laboratory Findings
Laboratory results
Urinalysis
 
On admission
10 weeks after treatment
At 6-month follow up
   
On admission
10 weeks after treatment
At 6-month follow up
 
WBC
9700
6900
10,200
/μL
Blood
3 + 
 
Hb
14.9
13.7
11.8
g/dL
RBC
 > 100
14
15
/hpf
Hct
42.3
40.7
34.1
%
protein
4 + 
 
Plt
49.9
40.9
37.2
104/μL
Protein/Cr
12.8
0.11
 < 0.03
g/gCr
CRP
0.01
 < 0.01
 < 0.01
mg/dL
         
AST
32
13
14
U/L
         
ALT
30
10
8
U/L
         
LDH
276
196
170
U/L
         
Na
136
139
139
mmol/L
         
K
4.9
4.7
4
mmol/L
         
BUN
12.8
8.6
13.3
mg/dL
         
Cr
0.45
0.44
0.51
mg/dL
         
eGFR
118
120
103
ml/min/1.73m2
         
TP
4.1
6.3
6.5
g/dL
         
Alb
1.4
4.2
4.3
g/dL
         
T-Chol
542
225
190
mg/dL
         
hpf high-power field, eGFR estimated glomerular filtration rate
Appendix
Available only for authorised users
Literature
2.
go back to reference Nagano C, Yamamura T, Horinouchi T, Aoto Y, Ishiko S, Sakakibara N, Shima Y, Nakanishi K, Nagase H, Iijima K, Nozu K (2020) Comprehensive genetic diagnosis of Japanese patients with severe proteinuria. Sci Rep 10(1):270CrossRefPubMedPubMedCentral Nagano C, Yamamura T, Horinouchi T, Aoto Y, Ishiko S, Sakakibara N, Shima Y, Nakanishi K, Nagase H, Iijima K, Nozu K (2020) Comprehensive genetic diagnosis of Japanese patients with severe proteinuria. Sci Rep 10(1):270CrossRefPubMedPubMedCentral
3.
go back to reference Timmermans S, Busch MH, Abdul-Hamid MA, Frenken LAM, Aarnoudse A-J, van Paasseen P (2022) primary podocytopathies after COVID-19 vaccination. Kidney Int Rep 7(4):892–894CrossRefPubMed Timmermans S, Busch MH, Abdul-Hamid MA, Frenken LAM, Aarnoudse A-J, van Paasseen P (2022) primary podocytopathies after COVID-19 vaccination. Kidney Int Rep 7(4):892–894CrossRefPubMed
4.
go back to reference Izzedine H, Bonilla M, Jhaveri KD (2021) Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? Nephrol Dial Transplant 36(9):1565–1569CrossRefPubMed Izzedine H, Bonilla M, Jhaveri KD (2021) Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? Nephrol Dial Transplant 36(9):1565–1569CrossRefPubMed
5.
go back to reference D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43(2):368–382CrossRefPubMed D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43(2):368–382CrossRefPubMed
6.
go back to reference Rosenberg AZ, Naicker S, Winkler CA, Kopp JB (2015) HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol 11(3):150–160CrossRefPubMed Rosenberg AZ, Naicker S, Winkler CA, Kopp JB (2015) HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol 11(3):150–160CrossRefPubMed
8.
go back to reference Velez JCQ, Caza T, Larsen CP (2020) COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 16(10):565–567CrossRefPubMedPubMedCentral Velez JCQ, Caza T, Larsen CP (2020) COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 16(10):565–567CrossRefPubMedPubMedCentral
9.
go back to reference Gaillard F, Ismael S, Sannier A, Tarhini H, Volpe T, Greze C, Verpont MC, Zouhry I, Rioux C, Lescure F-X, Buob D, Daugas E (2020) Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy. Kidney Int 98(1):241CrossRefPubMedPubMedCentral Gaillard F, Ismael S, Sannier A, Tarhini H, Volpe T, Greze C, Verpont MC, Zouhry I, Rioux C, Lescure F-X, Buob D, Daugas E (2020) Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy. Kidney Int 98(1):241CrossRefPubMedPubMedCentral
Metadata
Title
Steroid resistant nephrotic syndrome with collapsing focal segmental glomerulosclerosis in a 12-year-old Japanese female after SARS-CoV-2 vaccination
Authors
Tomoko Horinouchi
Chika Ueda
Hideaki Kitakado
Norishige Yoshikawa
Kandai Nozu
Publication date
16-02-2023
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2023
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-023-01577-0

Other articles of this Issue 5/2023

Journal of Nephrology 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.